Table 1.
Individual Clinicopathologic Data of Patients with Non-Small Cell Lung Cancer Harboring Novel EGFR Fusions
| Patient No. | Ethnicity | Age/Gender | Smoking Status | Diagnosis | EGFR Fusion | Drug | Response | PFS, mo |
|---|---|---|---|---|---|---|---|---|
| 17 | South Asian | 35/F | Never | ADC/IV | EGFR-RAD51 | Erlotinib | PR | >8 |
| 27 | Caucasian | 21/F | Prev/Curr | ADC/IV | EGFR-RAD51 | Erlotinib | PR | >5 |
| 37 | Caucasian | 43/F | Prev/Curr | ADC/IV | EGFR-PURB | Erlotinib | PR | >20 |
| 47 | Caucasian | 38/M | Prev/Curr | ADC/IV | EGFR-RAD51 | Erlotinib | PR | >6 |
| 57 | Caucasian | 60/F | Never | ADC/IV | EGFR-RAD51 | Pemetrexed | PR | NA |
| 66,11 | American | NA/F | Prev/Curr | ADC/NA | EGFR-TNS3 | NA | NA | NA |
| 76,11 | American | NA/M | Never | SCC/NA | EGFR-ZCCHC6 | NA | NA | NA |
| 86 | Chinese | 48/M | Prev/Curr | ADC/IV | EGFR-RAD51 | Erlotinib | PR | >5 |
| 912 | Chinese | 26/M | Never | ADC/IV | EGFR-RAD51 | Icotinib | PR | >15 |
| 1010 | American | 62/F | Never | ADC/IV | EGFR-RAD51 | Afatinib | SD | >6 |
| 119 | Chinese | 62/F | NA | ADC/NA | EGFR-SEPTIN14 | Icotinib | PR | NA |
| 128 | Chinese | 61/M | Prev/Curr | ADC/IIIA | EGFR-SHC1 | NA | NA | NA |
| 1326 | American | 36/M | NA | NSCLC/IV | EGFR-RAD51 | Erlotinib | PR | >24 |
| 1427 | Chinese | 45/F | NA | ADC/NA | KIF5B-EGFR | Afatinib/ | PR | >10 |
| Bevacizumab | ||||||||
| 15 | Chinese | 50/M | Prev/Curr | ADC/IV | KIF5B-EGFR | Afatinib | PR | 11 |
Abbreviations: PFS, progression-free survival; mo, months; F, female; M, male; NA, not available; Prev, previous; Curr, current; PR, partial remission; SD, stable disease.